| 臺大學術典藏 |
2022-05-12T07:37:59Z |
Low miR-10b-3p associated with sorafenib resistance in hepatocellular carcinoma
|
Shao, Yu-Yun; Chen, Pai-Sheng; LIANG-IN LIN; Lee, Bin-Shyun; Ling, Andrew; Cheng, Ann-Lii; CHIUN HSU; Ou, Da-Liang |
| 臺大學術典藏 |
2022-05-05T03:26:21Z |
Spectrum of cancer patients receiving renal biopsy
|
FAN-CHI CHANG; Chen, Tom Wei-Wu; Huang, Thomas Tao-Min; Lin, Wei-Chou; Liu, Jia-Sin; Chiang, Wen-Chih; Chen, Yung-Ming; CHIUN HSU; Yeh, Kun-Huei; Chu, Tzong-Shinn |
| 臺大學術典藏 |
2022-04-14T07:44:52Z |
Association of annexin A10 expression with poor prognosis of intrahepatic cholangiocarcinoma
|
Shao, Yu-Yun; Kuo, Hung-Yang; Jeng, Yung-Ming; YAO-MING WU; Wang, Hsiu-Po; CHIUN HSU; CHIH-HUNG HSU; Hsu, Hey-Chi; Cheng, Ann-Lii; Lin, Zhong-Zhe |
| 臺大學術典藏 |
2022-03-14T23:45:18Z |
Low miR-10b-3p associated with sorafenib resistance in hepatocellular carcinoma
|
YU-YUN SHAO; Chen, Pai Sheng; LIANG-IN LIN; Lee, Bin Shyun; Ling, Andrew; ANN-LII CHENG; CHIUN HSU; DA-LIANG OU |
| 臺大學術典藏 |
2022-03-14T23:44:59Z |
Association of annexin A10 expression with poor prognosis of intrahepatic cholangiocarcinoma
|
YU-YUN SHAO; HUNG-YANG KUO; YUNG-MING JENG; YAO-MING WU; HSIU-PO WANG; CHIUN HSU; CHIH-HUNG HSU; Hsu, Hey Chi; ANN-LII CHENG; Lin, Zhong Zhe |
| 臺大學術典藏 |
2022-01-24T06:05:36Z |
Potential of circulating immune cells as biomarkers of nivolumab treatment efficacy for advanced hepatocellular carcinoma
|
Hung Y.-P.; Shao Y.-Y.; Lee J.-M.; CHIUN HSU; Hsieh C.-H.; Yang M.-H.; Chao Y. |
| 臺大學術典藏 |
2022-01-24T06:05:35Z |
The unique characteristic in peripheral immune cells in patients with advanced hepatocellular carcinoma
|
Hung Y.-P.; Shao Y.-Y.; CHIUN HSU; Hsieh C.-H.; Lee J.-M.; Yang M.-H.; Chao Y. |
| 臺大學術典藏 |
2022-01-24T06:05:35Z |
Management consensus guideline for hepatocellular carcinoma: 2020 update on surveillance, diagnosis, and systemic treatment by the Taiwan Liver Cancer Association and the Gastroenterological Society of Taiwan
|
Shao Y.-Y.; Wang S.-Y.; Lin S.-M.; Chen K.-Y.; Tseng J.-H.; Ho M.-C.; Lee R.-C.; Liang P.-C.; Liao L.-Y.; Huang K.-W.; Hu J.-T.; Liang J.-D.; Kee K.-M.; Lin C.-L.; Wang C.-K.; Lu S.-N.; Wang J.-H.; Lee W.-C.; Chen C.-H.; Liu C.-J.; Huang Y.-H.; Wang C.-C.; Wang T.-E.; Chuang P.-H.; Dai C.-Y.; CHIUN HSU; Chen S.-C.; Hsieh C.-H.; Diagnosis Group, Systemic Therapy Group |
| 臺大學術典藏 |
2022-01-24T06:05:35Z |
Eg5 as a prognostic biomarker and potential therapeutic target for hepatocellular carcinoma
|
Shao Y.-Y.; Sun N.-Y.; Jeng Y.-M.; Wu Y.-M.; CHIUN HSU; Hsieh C.-H.; Hsu H.-C.; Cheng A.-L.; Lin Z.-Z. |
| 臺大學術典藏 |
2022-01-24T06:05:34Z |
Early changes in dce-mri biomarkers may predict survival outcomes in patients with advanced hepatocellular carcinoma after sorafenib failure: Two prospective phase ii trials
|
Chen B.-B.; Lin Z.-Z.; Shao Y.-Y.; CHIUN HSU; Hsieh C.-H.; Cheng A.-L.; Liang P.-C.; Shih T.T.-F. |
| 臺大學術典藏 |
2022-01-24T06:05:33Z |
Spectrum of cancer patients receiving renal biopsy
|
Chang F.-C.; Chen T.W.-W.; Huang T.T.-M.; Lin W.-C.; Liu J.-S.; Chiang W.-C.; Chen Y.-M.; CHIUN HSU; Yeh K.-H.; Chu T.-S. |
| 臺大學術典藏 |
2022-01-24T06:05:32Z |
Potential Role of CXCL13/CXCR5 Signaling in Immune Checkpoint Inhibitor Treatment in Cancer
|
Hsieh C.-H.; Jian C.-Z.; Lin L.-I.; Low G.-S.; Ou P.-Y.; CHIUN HSU; Ou D.-L. |
| 臺大學術典藏 |
2022-01-15T00:07:52Z |
Potential Role of CXCL13/CXCR5 Signaling in Immune Checkpoint Inhibitor Treatment in Cancer
|
Hsieh, Ching Hung; Jian, Cheng Zhe; LIANG-IN LIN; Low, Guan Sian; Ou, Ping Yun; CHIUN HSU; DA-LIANG OU |
| 臺大學術典藏 |
2022-01-15T00:07:49Z |
Fully digital problem-based learning for undergraduate medical students during the COVID-19 period: Practical considerations
|
CHIA-TER CHAO; Tsai, Chiao Lin; Lin, Mong Wei; CHIH-WEI YANG; CHAO-CHI HO; HUEY-LING CHEN; CHIUN HSU; BOR-CHING SHEU |
| 臺大學術典藏 |
2022-01-14T03:38:07Z |
A Multicenter Phase II Study of Second-Line Axitinib for Patients with Advanced Hepatocellular Carcinoma Failing First-Line Sorafenib Monotherapy
|
Lin, Zhong-Zhe; Chen, Bang-Bin; Hung, Yi-Ping; HUANG, PO-HSIANG; Shen, Ying-Chun; Shao, Yu-Yun; Hsu, Chih-Hung; Cheng, Ann-Lii; Lee, Rheun-Chuan; Chao, Yee; Chiun Hsu |
| 臺大學術典藏 |
2021-12-16T03:39:19Z |
Dynamic Contrast-Enhanced and Intravoxel Incoherent Motion MRI Biomarkers Are Correlated to Survival Outcome in Advanced Hepatocellular Carcinoma
|
Chen, Bang-Bin; Shao, Yu-Yun; Lin, Zhong-Zhe; Hsu, Chih-Hung; Cheng, Ann-Lii; CHIUN HSU; Liang, Po-Chin; TIFFANY TING-FANG SHIH |
| 臺大學術典藏 |
2021-12-16T03:25:51Z |
Early Changes in DCE-MRI Biomarkers May Predict Survival Outcomes in Patients with Advanced Hepatocellular Carcinoma after Sorafenib Failure: Two Prospective Phase II Trials
|
Chen, Bang-Bin; Lin, Zhong-Zhe; Shao, Yu-Yun; CHIUN HSU; Hsu, Chih-Hung; Cheng, Ann-Lii; Liang, Po-Chin; TIFFANY TING-FANG SHIH |
| 臺大學術典藏 |
2021-12-16T02:10:26Z |
Dynamic Contrast-Enhanced and Intravoxel Incoherent Motion MRI Biomarkers Are Correlated to Survival Outcome in Advanced Hepatocellular Carcinoma
|
BANG-BIN CHEN; Shao, Yu-Yun; Lin, Zhong-Zhe; Hsu, Chih-Hung; Cheng, Ann-Lii; CHIUN HSU; Liang, Po-Chin; Shih, Tiffany Ting-Fang |
| 臺大學術典藏 |
2021-12-16T02:03:28Z |
Early Changes in DCE-MRI Biomarkers May Predict Survival Outcomes in Patients with Advanced Hepatocellular Carcinoma after Sorafenib Failure: Two Prospective Phase II Trials
|
BANG-BIN CHEN; Lin, Zhong-Zhe; Shao, Yu-Yun; CHIUN HSU; Hsu, Chih-Hung; Cheng, Ann-Lii; Liang, Po-Chin; Shih, Tiffany Ting-Fang |
| 臺大學術典藏 |
2021-12-15T07:39:40Z |
Dynamic Contrast-Enhanced and Intravoxel Incoherent Motion MRI Biomarkers Are Correlated to Survival Outcome in Advanced Hepatocellular Carcinoma
|
Chen, Bang-Bin; Shao, Yu-Yun; Lin, Zhong-Zhe; Hsu, Chih-Hung; Cheng, Ann-Lii; CHIUN HSU; PO-CHIN LIANG; Shih, Tiffany Ting-Fang |
| 臺大學術典藏 |
2021-12-15T07:29:31Z |
Early Changes in DCE-MRI Biomarkers May Predict Survival Outcomes in Patients with Advanced Hepatocellular Carcinoma after Sorafenib Failure: Two Prospective Phase II Trials
|
Chen, Bang-Bin; Lin, Zhong-Zhe; Shao, Yu-Yun; CHIUN HSU; Hsu, Chih-Hung; Cheng, Ann-Lii; PO-CHIN LIANG; Shih, Tiffany Ting-Fang |
| 臺大學術典藏 |
2021-11-24T08:20:52Z |
Eg5 as a Prognostic Biomarker and Potential Therapeutic Target for Hepatocellular Carcinoma
|
Shao, Yu-Yun; Sun, Nai-Yun; Jeng, Yung-Ming; YAO-MING WU; CHIUN HSU; Hsu, Chih-Hung; Hsu, Hey-Chi; Cheng, Ann-Lii; Lin, Zhong-Zhe |
| 臺大學術典藏 |
2021-09-14T23:18:28Z |
Eg5 as a Prognostic Biomarker and Potential Therapeutic Target for Hepatocellular Carcinoma
|
YU-YUN SHAO; Sun, Nai Yun; YUNG-MING JENG; YAO-MING WU; CHIUN HSU; CHIH-HUNG HSU; Hsu, Hey Chi; ANN-LII CHENG; Lin, Zhong Zhe |
| 臺大學術典藏 |
2021-08-15T00:08:05Z |
Dynamic contrast-enhanced and intravoxel incoherent motion mri biomarkers are correlated to survival outcome in advanced hepatocellular carcinoma
|
BANG-BIN CHEN; YU-YUN SHAO; Lin, Zhong Zhe; CHIH-HUNG HSU; ANN-LII CHENG; CHIUN HSU; PO-CHIN LIANG; TIFFANY TING-FANG SHIH |
| 臺大學術典藏 |
2021-08-09T08:17:29Z |
Introduction of the EORTC Disease-Specific Quality of Life Questionnaires for Cancer Patients
|
Wei-Chu Chie; Chih-Hsin Yang; CHIUN HSU; Chia-Chun Lai |
| 臺大學術典藏 |
2021-08-06T03:59:35Z |
Group Report Contest Enhances Problem-Based Learning
|
Jeng-Yi Shieh; Chien-An Yao; CHIUN HSU; Shan-Chwen Chang; Fen-Yu Tseng |
| 臺大學術典藏 |
2021-08-06T03:52:20Z |
The Learning Experiences of Medical and Pharmacy Students Participating in Interdisciplinary Problem-Based Small-group Discussions
|
Chia-Hsuin Chang; CHIUN HSU; Chao-Chi Ho; Hsiu-Ying Wu; Ai-Tzu Li; Fen-Yu Tseng |
| 臺大學術典藏 |
2021-08-06T03:45:52Z |
Students' Perspective on the Key Elements and Effectiveness of Problem-based Learning Group Discussion
|
Chia-Hsuin Chang; CHIUN HSU; Chao-Chi Ho; Hsiu-Ying Wu; Ai-Tzu Li; Fen-Yu Tseng |
| 臺大學術典藏 |
2021-08-06T03:38:36Z |
Gap in the Intensity of End-of-Life Care between Younger and Older Taiwanese Adult Cancer Patients may not Reflect Younger Patients' Preferences
|
Siew-Tzuh Tang; Tsang-Wu Liu; Jyh-Ming Chow; Chang-Fang Chiu; CHIUN HSU; Li-Ni Liu; Su-Ching Kuo |
| 臺大學術典藏 |
2021-08-06T03:26:51Z |
Targeted Therapy for Hepatocellular Carcinoma
|
CHIUN HSU; Ying-Chun Shen; Ann-Lii Cheng |
| 臺大學術典藏 |
2021-07-15T05:31:54Z |
Adjuvant versus Neoadjuvant Immunotherapy for Hepatocellular Carcinoma: Clinical and Immunologic Perspectives
|
Su, Yung Yeh; Li, Chia Chen; Lin, Yih Jyh; CHIUN HSU |
| 臺大學術典藏 |
2021-07-15T05:31:28Z |
Exploring Markers of Exhausted CD8 T Cells to Predict Response to Immune Checkpoint Inhibitor Therapy for Hepatocellular Carcinoma
|
Chia-Lang Hsu; DA-LIANG OU; Bai, Li Yuan; Chen, Chia Wei; Lin, Li; Huang, Shiu Feng; ANN-LII CHENG; YUNG-MING JENG; CHIUN HSU |
| 臺大學術典藏 |
2021-05-13T06:17:53Z |
Spectrum of cancer patients receiving renal biopsy
|
Chang, Fan-Chi; Chen, Tom Wei-Wu; Huang, Thomas Tao-Min; Lin, Wei-Chou; Liu, Jia-Sin; WEN-CHIH CHIANG; Chen, Yung-Ming; CHIUN HSU; Yeh, Kun-Huei; Chu, Tzong-Shinn |
| 臺大學術典藏 |
2021-05-13T01:56:55Z |
Spectrum of cancer patients receiving renal biopsy
|
Chang, Fan-Chi; Chen, Tom Wei-Wu; Huang, Thomas Tao-Min; Lin, Wei-Chou; Liu, Jia-Sin; Chiang, Wen-Chih; YUNG-MING CHEN; CHIUN HSU; Yeh, Kun-Huei; Chu, Tzong-Shinn |
| 臺大學術典藏 |
2021-04-21T23:30:44Z |
Regorafenib enhances antitumor immunity via inhibition of p38 kinase/Creb1/Klf4 axis in tumor-associated macrophages
|
DA-LIANG OU; Chen, Chia Wei; Chia-Lang Hsu; Chung, Chih Hung; Feng, Zi Rui; Lee, Bin Shyun; ANN-LII CHENG; Yang, Muh Hwa; CHIUN HSU |
| 臺大學術典藏 |
2021-03-14T23:24:21Z |
Spectrum of cancer patients receiving renal biopsy
|
Chang, Fan Chi; Chen, Tom Wei Wu; Huang, Thomas Tao Min; WEI-CHOU LIN; Liu, Jia Sin; WEN-CHIH CHIANG; YUNG-MING CHEN; Chiun Hsu; KUN-HUEI YEH; TZONG-SHINN CHU |
| 臺大學術典藏 |
2021-02-18T02:33:48Z |
Differential Organ-Specific Tumor Response to Immune Checkpoint Inhibitors in Hepatocellular Carcinoma
|
Lu L.-C.;Shao Y.-Y.;Chao Y.;Yen C.-J.;Shih I.-L.;Hung Y.-P.;Chang C.-J.;Shen Y.-C.;Guo J.-C.;Liu T.-H.;Chiun Hsu;Cheng A.-L.; Lu L.-C.; Shao Y.-Y.; Chao Y.; Yen C.-J.; Shih I.-L.; Hung Y.-P.; Chang C.-J.; Shen Y.-C.; Guo J.-C.; Liu T.-H.; Chiun Hsu; Cheng A.-L. |
| 臺大學術典藏 |
2021-02-18T02:33:48Z |
Early alpha-foetoprotein response associated with treatment efficacy of immune checkpoint inhibitors for advanced hepatocellular carcinoma
|
Shao Y.-Y.;Liu T.-H.;Chiun Hsu;Lu L.-C.;Shen Y.-C.;Lin Z.-Z.;Cheng A.-L.; Shao Y.-Y.; Liu T.-H.; Chiun Hsu; Lu L.-C.; Shen Y.-C.; Lin Z.-Z.; Cheng A.-L. |
| 臺大學術典藏 |
2021-02-18T02:33:48Z |
Klotho-beta and fibroblast growth factor 19 expression correlates with early recurrence of resectable hepatocellular carcinoma
|
Lin Z.-Z.;Chiun Hsu;Jeng Y.-M.;Hu F.-C.;Pan H.-W.;Wu Y.-M.;Hsu H.-C.;Cheng A.-L.; Lin Z.-Z.; Chiun Hsu; Jeng Y.-M.; Hu F.-C.; Pan H.-W.; Wu Y.-M.; Hsu H.-C.; Cheng A.-L. |
| 臺大學術典藏 |
2021-02-18T02:33:47Z |
Pan-Asian adapted ESMO Clinical Practice Guidelines for the management of patients with intermediate and advanced/relapsed hepatocellular carcinoma: a TOS�VESMO initiative endorsed by CSCO, ISMPO, JSMO, KSMO, MOS and SSO
|
Chen L.-T.;Martinelli E.;Cheng A.-L.;Pentheroudakis G.;Qin S.;Bhattacharyya G.S.;Ikeda M.;Lim H.-Y.;Ho G.F.;Choo S.P.;Ren Z.;Malhotra H.;Ueno M.;Ryoo B.-Y.;Kiang T.C.;Tai D.;Vogel A.;Cervantes A.;Lu S.-N.;Yen C.-J.;Huang Y.-H.;Chen S.-C.;Shen Y.-C.;Tabernero J.;Yen Y.;Chiun Hsu;Yoshino T.;Douillard J.-Y.; Chen L.-T.; Martinelli E.; Cheng A.-L.; Pentheroudakis G.; Qin S.; Bhattacharyya G.S.; Ikeda M.; Lim H.-Y.; Ho G.F.; Choo S.P.; Ren Z.; Malhotra H.; Ueno M.; Ryoo B.-Y.; Kiang T.C.; Tai D.; Vogel A.; Cervantes A.; Lu S.-N.; Yen C.-J.; Huang Y.-H.; Chen S.-C.; Shen Y.-C.; Tabernero J.; Yen Y.; Chiun Hsu; Yoshino T.; Douillard J.-Y. |
| 臺大學術典藏 |
2021-02-18T02:09:13Z |
Management consensus guideline for hepatocellular carcinoma: 2020 update on surveillance, diagnosis, and systemic treatment by the Taiwan Liver Cancer Association and the Gastroenterological Society of Taiwan
|
Shao Y.-Y.;Wang S.-Y.;Lin S.-M.;Chen K.-Y.;Tseng J.-H.;Ho M.-C.;Lee R.-C.;Liang P.-C.;Liao L.-Y.;Huang K.-W.;Hu J.-T.;Liang J.-D.;Kee K.-M.;Lin C.-L.;Wang C.-K.;Lu S.-N.;Wang J.-H.;Lee W.-C.;Chen C.-H.;Liu C.-J.;Huang Y.-H.;Wang C.-C.;Wang T.-E.;Chuang P.-H.;Dai C.-Y.;Chiun Hsu;Chen S.-C.;Hsieh C.-H.;Diagnosis Group, Systemic Therapy Group; Shao Y.-Y.; Wang S.-Y.; Lin S.-M.; Chen K.-Y.; Tseng J.-H.; Ho M.-C.; Lee R.-C.; Liang P.-C.; Liao L.-Y.; Huang K.-W.; Hu J.-T.; Liang J.-D.; Kee K.-M.; Lin C.-L.; Wang C.-K.; Lu S.-N.; Wang J.-H.; Lee W.-C.; Chen C.-H.; Liu C.-J.; Huang Y.-H.; Wang C.-C.; Wang T.-E.; Chuang P.-H.; Dai C.-Y.; Chiun Hsu; Chen S.-C.; Hsieh C.-H.; Diagnosis Group, Systemic Therapy Group |
| 臺大學術典藏 |
2021-02-18T02:09:13Z |
Corrigendum to Nivolumab in advanced hepatocellular carcinoma: Sorafenib-experienced Asian cohort analysis
|
Yau T.;Chiun Hsu;Kim T.-Y.;Choo S.-P.;Kang Y.-K.;Hou M.-M.;Numata K.;Yeo W.;Chopra A.;Ikeda M.;Kuromatsu R.;Moriguchi M.;Chao Y.;Zhao H.;Anderson J.;Dela Cruz C.;Kudo M.; Yau T.; Chiun Hsu; Kim T.-Y.; Choo S.-P.; Kang Y.-K.; Hou M.-M.; Numata K.; Yeo W.; Chopra A.; Ikeda M.; Kuromatsu R.; Moriguchi M.; Chao Y.; Zhao H.; Anderson J.; Dela Cruz C.; Kudo M. |
| 臺大學術典藏 |
2021-02-18T02:09:12Z |
The unique characteristic in peripheral immune cells in patients with advanced hepatocellular carcinoma
|
Hung Y.-P.;Shao Y.-Y.;Chiun Hsu;Lee J.-M.;Yang M.-H.;Chao Y.; Hung Y.-P.; Shao Y.-Y.; Chiun Hsu; Lee J.-M.; Yang M.-H.; Chao Y. |
| 臺大學術典藏 |
2021-02-18T02:09:12Z |
A multicenter, phase I/II trial of biweekly S-1, leucovorin, oxaliplatin and gemcitabine in metastatic pancreatic adenocarcinoma�VTCOG T1211 study
|
Chiang N.-J.;Tsai K.K.;Hsiao C.-F.;Yang S.-H.;Hsiao H.-H.;Shen W.-C.;Chiun Hsu;Lin Y.-L.;Chen J.-S.;Shan Y.-S.;Chen L.-T.; Chiang N.-J.; Tsai K.K.; Hsiao C.-F.; Yang S.-H.; Hsiao H.-H.; Shen W.-C.; Chiun Hsu; Lin Y.-L.; Chen J.-S.; Shan Y.-S.; Chen L.-T. |
| 臺大學術典藏 |
2021-02-18T02:09:12Z |
Efficacy and Safety of Nivolumab plus Ipilimumab in Patients with Advanced Hepatocellular Carcinoma Previously Treated with Sorafenib: The CheckMate 040 Randomized Clinical Trial
|
Yau T.;Kang Y.-K.;Kim T.-Y.;El-Khoueiry A.B.;Santoro A.;Sangro B.;Melero I.;Kudo M.;Hou M.-M.;Matilla A.;Tovoli F.;Knox J.J.;Ruth He A.;El-Rayes B.F.;Acosta-Rivera M.;Lim H.-Y.;Neely J.;Shen Y.;Wisniewski T.;Anderson J.;Chiun Hsu; Yau T.; Kang Y.-K.; Kim T.-Y.; El-Khoueiry A.B.; Santoro A.; Sangro B.; Melero I.; Kudo M.; Hou M.-M.; Matilla A.; Tovoli F.; Knox J.J.; Ruth He A.; El-Rayes B.F.; Acosta-Rivera M.; Lim H.-Y.; Neely J.; Shen Y.; Wisniewski T.; Anderson J.; Chiun Hsu |
| 臺大學術典藏 |
2021-02-18T02:09:11Z |
Challenges of combination therapy with immune checkpoint inhibitors for hepatocellular carcinoma
|
Cheng A.-L.;Chiun Hsu;Chan S.L.;Choo S.-P.;Kudo M.; Cheng A.-L.; Chiun Hsu; Chan S.L.; Choo S.-P.; Kudo M. |
| 臺大學術典藏 |
2021-02-18T01:45:22Z |
Pembrolizumab for the treatment of programmed death�Vligand 1?positive advanced carcinoid or pancreatic neuroendocrine tumors: Results from the KEYNOTE-028 study
|
Mehnert J.M.;Bergsland E.;O??Neil B.H.;Santoro A.;Schellens J.H.M.;Cohen R.B.;Doi T.;Ott P.A.;Pishvaian M.J.;Puzanov I.;Aung K.L.;Chiun Hsu;Le Tourneau C.;Hollebecque A.;?Lez E.;Tamura K.;Gould M.;Yang P.;Stein K.;Piha-Paul S.A.; Mehnert J.M.; Bergsland E.; O��Neil B.H.; Santoro A.; Schellens J.H.M.; Cohen R.B.; Doi T.; Ott P.A.; Pishvaian M.J.; Puzanov I.; Aung K.L.; Chiun Hsu; Le Tourneau C.; Hollebecque A.; ?lez E.; Tamura K.; Gould M.; Yang P.; Stein K.; Piha-Paul S.A. |
| 臺大學術典藏 |
2021-02-18T01:45:22Z |
Atezolizumab with or without bevacizumab in unresectable hepatocellular carcinoma (GO30140): an open-label, multicentre, phase 1b study
|
Lee M.S.;Ryoo B.-Y.;Numata K.;Stein S.;Verret W.;Hack S.P.;Spahn J.;Liu B.;Abdullah H.;Wang Y.;He A.R.;Lee K.-H.;Bang Y.-J.;Bendell J.;Chao Y.;Chen J.-S.;Chung H.C.;Davis S.L.;Dev A.;Gane E.;George B.;He A.R.;Hochster H.;Chiun Hsu;Ikeda M.;Lee J.;Lee M.;Mahipal A.;Manji G.;Morimoto M.;Numata K.;Pishvaian M.;Qin S.;Ryan D.;Ryoo B.-Y.;Sasahira N.;Stein S.;Strickler J.;Tebbutt N.; Lee M.S.; Ryoo B.-Y.; Numata K.; Stein S.; Verret W.; Hack S.P.; Spahn J.; Liu B.; Abdullah H.; Wang Y.; He A.R.; Lee K.-H.; Bang Y.-J.; Bendell J.; Chao Y.; Chen J.-S.; Chung H.C.; Davis S.L.; Dev A.; Gane E.; George B.; He A.R.; Hochster H.; Chiun Hsu; Ikeda M.; Lee J.; Lee M.; Mahipal A.; Manji G.; Morimoto M.; Numata K.; Pishvaian M.; Qin S.; Ryan D.; Ryoo B.-Y.; Sasahira N.; Stein S.; Strickler J.; Tebbutt N. |
| 臺大學術典藏 |
2021-02-18T01:45:22Z |
An Open-Label, Single-Arm, Two-Stage, Multicenter, Phase II Study to Evaluate the Efficacy of TLC388 and Genomic Analysis for Poorly Differentiated Neuroendocrine Carcinomas
|
Chen M.-H.;Chou W.-C.;Hsiao C.-F.;Jiang S.S.;Tsai H.-J.;Liu Y.-C.;Chiun Hsu;Shan Y.-S.;Hung Y.-P.;Hsich C.-H.;Chiu C.-H.;Liu T.-C.;Cho S.-F.;Liu T.-W.;Chao Y.; Chen M.-H.; Chou W.-C.; Hsiao C.-F.; Jiang S.S.; Tsai H.-J.; Liu Y.-C.; Chiun Hsu; Shan Y.-S.; Hung Y.-P.; Hsich C.-H.; Chiu C.-H.; Liu T.-C.; Cho S.-F.; Liu T.-W.; Chao Y. |
| 臺大學術典藏 |
2021-02-18T01:45:21Z |
Novel systemic therapy for hepatocellular carcinoma
|
Dong Y.;Liu T.-H.;Yau T.;Chiun Hsu; Dong Y.; Liu T.-H.; Yau T.; Chiun Hsu |
